PFE Stock Price Today (April 2026) — Pfizer Inc. Analysis & Key Metrics 2026-04-02
Pfizer Inc. (PFE) is trading at $27.26, down 4.52% today (as of April 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $28.58 (4.8% upside).
- Volatility remains elevated (19.84% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (-1.20% YoY) alongside significant competitive pressures.
PFE Stock Analysis: Key Metrics & Valuation (April 2026)
Concise, actionable data for investors
Pfizer Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $215.39B
P/E Ratio
Forward P/E: 10.03
Revenue Growth
Year over Year
Analyst Target
+4.8% upside potential
Key Investor Questions About PFE
What investors need to know before buying
Based on current market data, PFE presents a neutral technical setup with challenging fundamentals.
- Technicals say: Neutral (RSI 64.77)
- Fundamentals say: Challenging (declining revenue trends)
PFE's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for PFE investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $67.65B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, PFE stock traded between $20.92 and $28.75—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 19.84% annualized volatility and β=0.41, the stock exhibits low sensitivity to market moves—making PFE suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Q4 Earnings Highs And Lows: Pfizer (NYSE:PFE) Vs The Rest Of The Branded Pharmaceuticals Stocks
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers.
Is Pfizer (PFE) Offering Value After Its 31% One Year Share Price Jump
If you are wondering whether Pfizer at around US$27.47 is a bargain or a value trap, the key is understanding what the current price actually implies about the company. The stock is up 9.1% year to date and 31.0% over the last year, even though it shows a 3.8% decline over the past week and a 2.5% gain over the past month. These moves can change how the market views both its potential and its risks. Recent headlines have focused on Pfizer's shifting pipeline mix, product portfolio updates,...
Gilead Agrees $5 Billion Tubulis Acquisition To Expand Cancer Drug Pipeline
Biotech will pay $3.15 billion upfront plus milestones to acquire ADC-focused Tubulis, strengthening oncology pipeline and research capabilities.
How Pfizer's Oncology Portfolio Is Shaping Up Before Q1 Results
Pfizer's oncology unit displays mixed Q1 trends as key drugs and biosimilars offset Ibrance declines ahead of earnings on May 5
Assessing Novavax (NVAX) Valuation After Renewed Focus On Covid And Malaria Vaccine Deals
Novavax (NVAX) is back in focus after fresh attention on its Covid and malaria vaccine portfolio and existing collaborations with partners such as Sanofi, Pfizer, Takeda and Serum Life Sciences, prompting investors to reassess the stock’s recent swings. See our latest analysis for Novavax. The recent spotlight on Covid and malaria vaccines comes after a choppy period for the shares, with a 30 day share price return of a 20.04% decline, a 90 day share price return of a 4.72% gain, and a 1 year...
Pfizer Reshapes Portfolio With Seagen And Metsera As COVID Winds Shift
Pfizer (NYSE:PFE) is accelerating its transformation with acquisitions of Seagen and Metsera to expand in oncology and anti obesity treatments. The company is dealing with lower COVID related revenues and the halt of a key COVID vaccine trial while advancing mRNA and Lyme vaccine programs. Pfizer reports a pipeline of more than 100 candidates, alongside cost cutting efforts and balance sheet adjustments during this transition phase. For investors watching large pharma, Pfizer now sits at...
The $190 Billion ‘Diabesity’ Market Is Set to Explode. Lilly and Novo Face These Stock Catalysts.
The recent fixation on weight-loss drugs, a catchall term referring to GLP-1 medications like Wegovy and Zepbound, has brought Eli Lilly and Novo Nordisk squarely into the limelight. The combined market for both indications—chronic weight management and diabetes—is projected to be enormous. Morgan Stanley forecasts a “diabesity” total addressable market in the neighborhood of $190 billion in 2035.
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
Pfizer (PFE) concluded the recent trading session at $27.1, signifying a -2.62% move from its prior day's close.
Why Pfizer Stock Tumbled on Tuesday
One analyst reiterated his pessimistic view of the pharmaceutical titan's future.
Jefferies Reiterates Buy Rating on Valneva (VALN) After Phase 3 Data
Valneva SE (NASDAQ:VALN) is one of the 8 Most Oversold Strong Buy-Rated Stocks to Invest In. On March 23, 2026, Jefferies reiterated a Buy rating and $15 price target on Valneva SE (NASDAQ:VALN) following topline results from the Phase 3 VALOR trial of its Lyme disease vaccine candidate PF-07307405. Jefferies said that the stock reaction […]
Frequently Asked Questions
Common investor questions about Pfizer Inc.
Pfizer Inc. (PFE) is currently trading at $27.26. The RSI (14-day) is at 64.8, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $28.58 implies 4.8% upside from current levels. Volatility is low at 19.8% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Pfizer Inc. (PFE): The trailing P/E ratio is 20.82, which is in line with broader market averages. The forward P/E is 10.03, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 13.77, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 1.86. Price-to-Sales is 2.57. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 26 analysts covering PFE, the consensus price target is $28.58. This represents a 4.8% upside from the current price of $27.26. The range spans from a low target of $25.00 to a high target of $36.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Pfizer Inc. (PFE) pays a dividend with a current yield of approximately 6.26%. The annualized dividend rate is $1.72 per share. The payout ratio is 126.5%, which exceeds 100%—this means the company is paying out more than it earns, which may not be sustainable long-term. The most recent ex-dividend date was 2026-01-23.
Key risks for Pfizer Inc. (PFE) investors include: 1. Declining revenue (-1.2% YoY), indicating potential business headwinds. 2. Unsustainable dividend payout ratio (126%) could lead to a dividend cut. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Pfizer Inc.'s (PFE) current debt and financial health profile: Total debt stands at $67.65B. The debt-to-equity ratio is 77.96, which is moderate and generally manageable for most companies. The current ratio is 1.16, indicating adequate short-term liquidity. The quick ratio is 0.80. The company holds $13.60B in cash and equivalents. Free cash flow is positive at $13.43B, providing a cushion for debt servicing and shareholder returns.